Decera Clinical Education Oncology Podcast Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients
11 snips
Sep 4, 2025 In this insightful discussion, Dr. Zev A. Wainberg, a leading expert in pancreatic cancer research, joins fellow oncologists Dr. Paul E. Oberstein and Dr. Mark O’Hara to tackle the challenges of diagnosing and treating metastatic pancreatic cancer. They explore why late diagnoses are common and the potential of chemotherapy as both a palliative and life-extending option. Highlighting promising emerging therapies like KRAS inhibitors, they emphasize the importance of patient-centered discussions in treatment decisions and the growing interest in novel therapies.
AI Snips
Chapters
Transcript
Episode notes
Late Diagnosis Limits Curative Possibility
- Pancreatic cancer is often diagnosed too late, which limits curative options and makes treatment largely palliative.
- Tumor biology and late presentation make durable disease eradication unusually difficult compared with many other cancers.
Metastatic Presentation Drives Palliative Care
- Most patients present with metastatic disease, so discussions and choices focus on palliative systemic therapy.
- Recent advances incrementally improve survival but have not yet produced transformational change.
Systemic Insult Often Limits Treatment
- Many patients already have systemic effects like weight loss, inflammation, and cachexia by the time they see specialists.
- These systemic insults often limit treatment tolerance and the potential for meaningful recovery.